|
Albuquerque, NM (Jan. 25,
2010) – Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD)
(www.biomoda.com)
today applauded Nebraska State Sen. Bob Krist and his co-sponsors
for introducing legislation to screen up to 500 Nebraska veterans
for early-stage lung cancer.
“The Nebraska Legislature
has taken another step toward saving lives,” said Biomoda
President and CEO John Cousins. “Lung cancer is the
deadliest cancer killer, primarily because it is too difficult and
too expensive to diagnose in its earliest stages when it is most
treatable.”
If Legislative Bill 987 is
enacted, the Nebraska Department of Veterans’ Affairs would
receive $650,000 to contract with the University of Nebraska
Medical Center Eppley Institute for Research in Cancer and Allied
Diseases to conduct the screening program based on a non-invasive
diagnostic tool developed by Biomoda and currently in clinical
trials. Biomoda’s CyPath® diagnostic is for
investigational use only pending approval by the U.S. Food and
Drug Administration (FDA).
“Veterans of the armed
services are at least 25 percent more likely than the general
population to be diagnosed with lung cancer. Screening
programs like the one proposed by this bill in Nebraska and an
earlier one enacted by the New Mexico Legislature help us
spotlight one of the most serious health issues facing the men and
women who serve in uniform,” Cousins said. “We want to
acknowledge Sen. Krist, who is himself a retired Air Force
lieutenant colonel, for introducing this bill, and we look forward
to working with the Eppley Institute which is internationally
renowned for its research on the causes, diagnosis and treatment
of cancer.”
If the Nebraska study is
funded, volunteers will provide a deep-lung sputum sample to be
tested for cancer cells with the CyPath® labeling solution, a
porphyrin-based compound that preferentially binds to cancer cells
and causes them to fluoresce red under ultraviolet light.
Results will be compared to a computed tomography (CT) scan,
currently the standard of care for detection of lung cancer, and
sputum Pap stains read by independent cytopathologists.
About Biomoda
Biomoda (www.biomoda.com)
is a cancer diagnostics company focused on the development of
accurate, inexpensive and noninvasive tests for the early
detection of cancer. Current research and development operations,
laboratory functions for both microscopy and assay formulation,
and administrative offices are located in Albuquerque, NM.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are based on
estimates, projections, beliefs and assumptions of Biomoda
management at the time of such statements and are not guarantees
of future performance. Forward-looking statements involve risks
and uncertainties in predicting future results and conditions.
Actual results could differ materially from those projected in
these forward-looking statements due to a variety of factors,
including, without limitation, the acceptance by customers of our
products, our ability to develop new products cost-effectively,
our ability to raise capital in the future, the development by
competitors of products using improved or alternative technology,
the retention of key employees and general economic conditions.
Forward-looking statements are made as of the date of this press
release and are subject to change without notice.
CONTACT:
Biomoda, Inc.
John
Cousins
505.821.0875
investor@biomoda.com
|
